Phathom Pharmaceuticals (PHAT) 8-K Summary
Phathom announced dosing of the first patient in its Phase 2 pHalcon EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan) for eosinophilic esophagitis (EoE) in adults.
- Trial Details: Two-part, randomized, double-blind, placebo-controlled study enrolling 80 adults.
- Guidance: Topline primary and secondary results are anticipated in 2027.
- Risk Factors: The company cautions that risks include trial delays, receiving negative or mixed results, and the possibility of not advancing the EoE program or securing pedi